Global Pharma Grade Glycine Market Size By Type (Chloroacetic Acid Amide Solution, Biosynthesis), By Application (Hospitals, Labs), By Region, And Segment Forecasts, 2023 to 2032

The Global Pharma Grade Glycine Market was valued at USD 245.6 million in 2023 and is projected to reach USD 418.3 million by 2031, growing at a CAGR of 6.9% during the forecast period from 2023 to 2031. Pharma grade glycine, a non-essential amino acid, is widely used in pharmaceutical formulations as a buffering agent, stabilizer, and excipient in antacids, analgesics, and other medications. The rising demand for glycine in parenteral solutions and its growing utilization in pharmaceutical R&D are driving significant growth in this market. As the pharmaceutical industry continues to expand, the demand for high-purity excipients like glycine is expected to rise steadily.

Drivers:

1. Increasing Pharmaceutical R&D and Drug Production:

As pharmaceutical research intensifies globally, there is growing demand for high-purity excipients such as pharma grade glycine, especially in injectable drug formulations and protein-based therapies.

2. Rising Prevalence of Chronic Diseases:

With chronic diseases such as cancer, diabetes, and cardiovascular conditions on the rise, demand for safe and effective drug formulations is increasing, subsequently boosting the consumption of pharma grade glycine.

3. Regulatory Compliance and Quality Standards:

The pharmaceutical industry's strict adherence to quality standards has driven demand for pharma grade glycine that meets USP, JP, and EP standards, ensuring safety and efficacy in drug formulations.

Restraints:

1. High Production Costs:

The production of pharma grade glycine involves stringent purification processes and quality assurance, which increases overall production costs and limits profit margins, especially for smaller players.

2. Limited Awareness in Developing Regions:

While demand is strong in North America and Europe, lack of awareness and limited infrastructure in emerging markets can restrain market expansion.

Opportunity:

1. Expansion into Emerging Healthcare Markets:

With healthcare infrastructure rapidly developing in Asia-Pacific, Latin America, and Africa, manufacturers have significant opportunities to tap into underpenetrated markets by promoting pharma grade glycine applications.

2. Innovation in Injectable Drug Delivery Systems:

The increasing use of injectable therapies and biologics presents strong growth potential for pharma grade glycine, which is extensively used as a stabilizing agent in these formulations.

Market by System Type Insights:

By system type, USP Grade Glycine accounted for the largest share of the market in 2023. Its widespread use in injectable drugs, oral formulations, and as a carrier in APIs underpins its dominance. JP/EP Grade Glycine is expected to witness the fastest growth due to increasing pharmaceutical exports to regions with strict pharmacopoeial standards.

Market by End-use Insights:

In 2023, the Pharmaceutical Companies segment held the largest market share, driven by the high demand for glycine in bulk drug production and injectable therapies. The Contract Manufacturing Organizations (CMOs) segment is expected to grow at the highest rate, as outsourcing pharmaceutical production becomes more common due to cost-efficiency and scalability benefits.

Market by Regional Insights:

North America led the global pharma grade glycine market in 2023, attributed to its strong pharmaceutical manufacturing base, R&D capabilities, and favorable regulatory framework. Asia-Pacific is expected to grow at the highest CAGR, driven by the expansion of generic drug manufacturing and increased investments in healthcare infrastructure in countries like India, China, and South Korea.

Competitive Scenario:

Leading players in the market include Ajinomoto Co., Inc., Evonik Industries AG, Yuki Gosei Kogyo Co., Ltd., Showa Denko K.K., GEO Specialty Chemicals, and Pharmavit GmbH. These companies focus on capacity expansion, mergers & acquisitions, and compliance with international standards to maintain a competitive edge.

Key Market Developments:

2023: Ajinomoto expanded its pharmaceutical-grade amino acid production facility in Japan to cater to growing global demand for glycine in injectable drugs.

2024: Evonik Industries AG announced a strategic partnership with a biotech firm to develop glycine-based stabilizers for next-gen biologics.

2025: Yuki Gosei Kogyo received EU GMP certification for its pharma-grade glycine production plant, strengthening its presence in European markets.

Scope of Work – Global Pharma Grade Glycine Market

Report Metric Details

Market Size (2023) USD 245.6 million

Projected Market Size (2031) USD 418.3 million

CAGR (2023-2031) 6.9%

Market Segments By System Type (USP Grade, JP/EP Grade), By End-use (Pharmaceutical Companies, CMOs), By Region

Growth Drivers Pharmaceutical R&D growth, injectable drug demand, chronic disease prevalence

Opportunities Emerging markets expansion, biologics and injectable formulations

FAQs:

1. What is the current market size of the Global Pharma Grade Glycine Market?

The market was valued at USD 245.6 million in 2023.

2. What is the major growth driver of the Global Pharma Grade Glycine Market?

The rising demand for high-purity excipients in pharmaceutical formulations, particularly in injectables and biologics, is the major growth driver.

3. Which is the largest region during the forecast period in the Global Pharma Grade Glycine Market?

North America is currently the largest region, but Asia-Pacific is projected to witness the fastest growth.

4. Which segment accounted for the largest market share in Global Pharma Grade Glycine Market?

The USP Grade Glycine segment held the largest share in 2023 due to its wide-ranging pharmaceutical applications.

5. Who are the key market players in the Global Pharma Grade Glycine Market?

Key players include Ajinomoto Co., Inc., Evonik Industries AG, Yuki Gosei Kogyo Co., Ltd., Showa Denko K.K., GEO Specialty Chemicals, and Pharmavit GmbH.